How We Perform Photodynamic Therapy MAL in Clinical Practice

  • Hannah C. de Vijlder
  • H. A. Martino Neumann


Many clinical trials have been reported on MAL-PDT for treating nonmelanoma skin cancer (NMSC), and acne vulgaris. Although response rates are high for NMSC, they do not match the response rates of (Mohs’ micrographic) surgery, especially for deeper lesions. The delivery of sufficient (precursor of) PpIX and light to the full depth of the lesion and sufficient supply of oxygen are critical in topical PDT. Optimization of these factors to improve the response rates for the deeper lesions is an area under investigation. Beside this technical limitation, pain associated with PDT is an important patient-related limitation of PDT. Although a lot of research has been done into the efficiency of PDT, more work needs to be done on the effect of various treatment variables on the efficiency and adverse effects of PDT in order to develop an optimum treatment protocol for both NMSC and acne vulgaris.


Basal Cell Carcinoma Fluence Rate Light Dose Intense Pulse Light Nonmelanoma Skin Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Robinson DJ, de Bruijn HS, Star WM. Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem Photobiol. 2003;77:319–23.PubMedCrossRefGoogle Scholar
  2. 2.
    De Haas ERM, Kruijt BM Sterenborg HJ. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol. 2006;126:2679–86.PubMedCrossRefGoogle Scholar
  3. 3.
    De Haas ERM, de Vijlder HC, Sterenborg HJ. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. J Eur Acad Dermatol Venereol. 2008;22:426–30.PubMedCrossRefGoogle Scholar
  4. 4.
    De Bruijn HS, de Haas ERM, Hebeda KM. Light fractionation does not enhance the efficacy of methyl 5-aminolevulinate mediated photodynamic therapy in normal Mouse skin. Photochem Photobiol Sc. 2007;6:1325–31.CrossRefGoogle Scholar
  5. 5.
    Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol. 2006;54:647–51.PubMedCrossRefGoogle Scholar
  6. 6.
    Moloney FJ, Collins P. Randomized, double-blind, prospective study to compare topical 5-aminolevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol. 2007;157:87–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Braathen LR, Szeimeis R, Basset-Seguin N. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus. J Am Acad Dermatol. 2007;56:125–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Peng Q, Soler AM, Warloe T. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B. 2001;62:140–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Rhodes LE, de Rie MA, Leifsdottir R. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy versus surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143:1131–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Horfelt C, Funk J, Frohm-Nilson M. Topical methyl aminolevulinate photodynamic therapy for treatment of facial acne vulgaris of a randomized, controlled trial. Br J Dermatol. 2006;142:973–8.Google Scholar
  11. 11.
    Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. Br J Dermatol. 2006;154:969–76.PubMedCrossRefGoogle Scholar
  12. 12.
    Haedersdal M, Togsverd-Bo K, Wiegell SR. Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: a randomized controlled trial. J Am Acad Dermatol. 2008;58:387–94.PubMedCrossRefGoogle Scholar
  13. 13.
    Yeung CK, Shek SY, Bjerring P. A comparative study of intense pulsed light alone and its combination with photodynamic therapy for the treatment of facial acne in asian skin. Lasers Surg Med. 2007;39:1–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Taylor MN, Gonzalez ML. Practicalities of photodynamic therapy in acne vulgaris. Br J Dermatol. 2009;160:1140–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Wiegell SR, Skiveren J, Philipsen PA, Wulf HA. Pain during photodynamic therapy is associated with protoporhyrin IX fluorescence and fluence rate. Br J Dermatol. 2008;158:727–33.PubMedCrossRefGoogle Scholar
  16. 16.
    de Leeuw J, de Vijlder HC, Bjerring P. Liposomes in dermatology today. J Eur Acad Dermatol Venereol. 2009;23:505–16.PubMedCrossRefGoogle Scholar
  17. 17.
    Wennberg AM. Pain relief and other practical issues in photodynamic therapy. Australas J Dermatol. 2005;46:S3–4.PubMedGoogle Scholar
  18. 18.
    Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008;159:1245–66.PubMedCrossRefGoogle Scholar
  19. 19.
    Mikolajewsksa P, Lani V, Juzeniene A, et al. Topical aminolaevulinic acid- and aminolaevulinic acid methyl ester-based photodynamic therapy with red and violet light: influence of wavelength on pain and erythema. Br J Dermatol. 2009;161:1173–9.CrossRefGoogle Scholar
  20. 20.
    Cottrell WJ, Paquette AD, Keymel KR, et al. Irradiance-dependent photobleaching and pain in d-Aminolevulinic acid-photodynamic therapy of superficial basal cell carci­nomas. Clin Cancer Res. 2008;14:4475–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Hannah C. de Vijlder
    • 1
  • H. A. Martino Neumann
  1. 1.Department of DermatologyErasmus Medical Center RotterdamRotterdamThe Netherlands

Personalised recommendations